title: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
abstract: BACKGROUND
  Helicobacter pylori gastritis may progress to glandular atrophy and intestinal metaplasia, conditions that predispose to gastric cancer. Profound suppression of gastric acid is associated with increased severity of H pylori gastritis. This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastro-oesophageal reflux disease (GORD).
  
  
  METHODS
  A total of 231 H pylori positive GORD patients who had been treated for > or =12 months with omeprazole maintenance therapy (OM) were randomised to either continuation of OM (OM only; n = 120) or OM plus a one week course of omeprazole, amoxycillin, and clarithromycin (OM triple; n = 111). Endoscopy with standardised biopsy sampling as well as symptom evaluation were performed at baseline and after one and two years. Gastritis was assessed according to the Sydney classification system for activity, inflammation, atrophy, intestinal metaplasia, and H pylori density.
  
  
  RESULTS
  Corpus gastritis activity at entry was moderate or severe in 50% and 55% of the OM only and OM triple groups, respectively. In the OM triple group, H pylori was eradicated in 90 (88%) patients, and activity and inflammation decreased substantially in both the antrum and corpus (p<0.001, baseline v two years). Atrophic gastritis also improved in the corpus (p<0.001) but not in the antrum. In the 83 OM only patients with continuing infection, there was no change in antral and corpus gastritis activity or atrophy, but inflammation increased (p<0.01). H pylori eradication did not alter the dose of omeprazole required, or reflux symptoms.
  
  
  CONCLUSIONS
  Most H pylori positive GORD patients have a corpus predominant pangastritis during omeprazole maintenance therapy. Eradication of H pylori eliminates gastric mucosal inflammation and induces regression of corpus glandular atrophy. H pylori eradication did not worsen reflux disease or lead to a need for increased omeprazole maintenance dose. We therefore recommend eradication of H pylori in GORD patients receiving long term acid suppression.
authors.affiliation: Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. e.j.kuipers@erasmusmc.nl
authors.forename: E J
authors.initials: EJ
authors.lastname: Kuipers
authors.forename: G F
authors.initials: GF
authors.lastname: Nelis
authors.forename: E C
authors.initials: EC
authors.lastname: Klinkenberg-Knol
authors.forename: P
authors.initials: P
authors.lastname: Snel
authors.forename: D
authors.initials: D
authors.lastname: Goldfain
authors.forename: J J
authors.initials: JJ
authors.lastname: Kolkman
authors.forename: H P M
authors.initials: HP
authors.lastname: Festen
authors.forename: J
authors.initials: J
authors.lastname: Dent
authors.forename: P
authors.initials: P
authors.lastname: Zeitoun
authors.forename: N
authors.initials: N
authors.lastname: Havu
authors.forename: M
authors.initials: M
authors.lastname: Lamm
authors.forename: A
authors.initials: A
authors.lastname: Walan
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002908:Chronic Disease; D018450:Disease Progression; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004942:Esophagitis, Peptic / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005756:Gastritis / Q000382:microbiology* / Q000473:pathology; D005757:Gastritis, Atrophic / Q000517:prevention & control; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D011446:Prospective Studies; D011706:Pyloric Antrum / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009853:Omeprazole